Business News • PR NewsWire • Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients

Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients

Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients

TARRYTOWN, N.Y., March 23, 2021 /PRNewswire/ -- REGEN-COV also significantly shortened the duration of symptoms by 4 days All doses (8,000 mg, 2,400 mg and 1,200 mg) had similar efficacy across all endpoints Companion dose-ranging Phase 2 trial showed significant and comparable viral...

View More : https://www.prnewswire.com:443/news-releases/phase-3-trial-shows-regen-cov-casirivimab-with-imdevimab-antibody-cocktail-...

Releted News by prnewswire

Health Cost IQ Successfully Completes SOC 2 Certification

Alcimos : Action de groupe potentielle par des investisseurs dans les fonds du Crédit Suisse affectés par les développements de Greensill Capital

Crypto-Friendly Fintech Wirex Temporarily Pauses Recruiting New UK Customers

Precision Value & Health adquiere al líder en dedicación omnicanal mundial, Across Health

Precision Value & Health erwirbt den globalen Omnichannel-Engagement-Führer, Across Health